VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global capital markets expertise as the company advances its BiTAC oncology platform, including antibody-drug conjugates and T-cell engagers. #Biotech #Oncology

VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global capital markets expertise as the company advances its BiTAC oncology platform, including antibody-drug conjugates and T-cell engagers. #Biotech #Oncology

Onco-Innovations (ONCO) is advancing ONC010 toward first-in-human trials, completing a high-purity drug batch, progressing preclinical studies and aligning regulatory planning for a potential Phase I study. #Oncology #Biotech

Onco-Innovations (ONCO) is advancing ONC010 toward first-in-human trials, completing a high-purity drug batch, progressing preclinical studies and aligning regulatory planning for a potential Phase I study. #Oncology #Biotech

VERAXA Biotech (NASDAQ: VRXA) debuts on U.S. markets with its precision 'AND-gated' BiTAC cancer platform, early preclinical proof of concept, $27.5M in financing, and two key executive hires. A Swiss biotech to watch. #Oncology #Biotech

Lantern Pharma (NASDAQ: LTRN) receives USPTO Notice of Allowance for LP-284 blood cancer treatment patent, extending IP protection through 2042. The AI-developed therapy targets mantle cell lymphoma and double-hit lymphoma. #Oncology #Biotech

Lantern Pharma (NASDAQ: LTRN) receives USPTO Notice of Allowance for LP-284 blood cancer treatment patent, extending IP protection through 2042. The AI-developed therapy targets mantle cell lymphoma and double-hit lymphoma. #Oncology #Biotech

Nutriband (NASDAQ: NTRB) confirms its 910,904 outstanding warrants expire Sept. 30, 2026 at $6.43/share — no extension or repricing. That's nearly $5.86M in potential proceeds if fully exercised. Warrant holders should act before the deadline. #NTRB #Biotech

Nutriband (NASDAQ: NTRB) confirms its 910,904 outstanding warrants expire Sept. 30, 2026 at $6.43/share — no extension or repricing. That's nearly $5.86M in potential proceeds if fully exercised. Warrant holders should act before the deadline. #NTRB #Biotech

Tonix Pharmaceuticals (NASDAQ: TNXP) expands TONMYA Medicare coverage to 32 million lives, reaching 58% of U.S. Medicare beneficiaries. Total covered lives now at 166 million. Sales force grows to 150 reps. #Fibromyalgia #Biotech

Roth Capital Partners will host its 5th Annual Healthcare Opportunities Conference on Sept. 29, 2026, in New York City, bringing together 30+ public healthcare companies and top institutional investors for high-impact meetings and discussions. #Healthcare #Biotech

Quantum BioPharma (NASDAQ: QNTM) is developing Lucid-MS, a novel drug candidate targeting the enzyme behind myelin destruction in MS. With ~3 million people affected globally and no cure in sight, new approaches are urgently needed. #MultipleSclerosis #Biotech

VERAXA Biotech (NASDAQ: VRXA) is advancing its 'AND-gated' BiTAC cancer platform following its NASDAQ debut in June 2026. Early preclinical data and key leadership hires signal the Swiss biotech is gaining momentum in oncology drug development. #Oncology #Biotech

Seminis.xyz Seed innovation, global agriculture, biotech breakthrough #Agritech #Biotech #GlobalFarming #Innovation #DomainSale

Lantern Pharma (NASDAQ: LTRN) is hosting a live webinar showcasing its Open-Medicine AI platform for drug development. CEO Panna Sharma covers market opportunity, platform demo, and growth roadmap. Launched as withZeta.ai, OMAI is expanding beyond rare cancers. #Biotech #AI

Lantern Pharma (NASDAQ: LTRN) is hosting a live webinar showcasing its Open-Medicine AI platform for drug development. CEO Panna Sharma covers market opportunity, platform demo, and growth roadmap. Launched as withZeta.ai, OMAI is expanding beyond rare cancers. #Biotech #AI

Kairos Pharma (NYSE: KAPA) CSO Neil Bhowmick will present KROS-101 solid tumor research and moderate a cancer drug resistance session at the Discovery on Target Conference in Boston, Sept. 30. #Oncology #BioTech

Kairos Pharma (NYSE: KAPA) CSO Neil Bhowmick will present KROS-101 solid tumor research and moderate a cancer drug resistance session at the Discovery on Target Conference in Boston, Sept. 30. #Oncology #BioTech

Annovis Bio ($ANVS) partners with Weave Bio to use AI in preparing its NDA for buntanetap, targeting Alzheimer's and Parkinson's. Phase 3 enrollment hit 862 patients, topping the 760 target. Data expected March 2027. #Biotech #Alzheimers